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timing of surgery and the RT schedule could influence tumor 
dissemination and subsequently patient overall survival. We 
demonstrated the impact of NeoRT on metastatic spreading 
in a Scid mice model. After an irradiation of 2x5gy, we show 
more metastasis in the lung when the mice are operated at 
day 4 compared to day 11 (1). Here, our aim is to evaluate 
with functional MRI (fMRI) the impact of the radiation 
treatment on the tumor microenvironment and subsequently 
to identify non-invasive markers helping to determine the 
best timing to perform surgery for avoiding tumor spreading. 
 
Material and Methods: We used two models of NeoRT in mice 
we have previously developed: MDA-MB 231 and 4T1 cells 
implanted in the flank of mice (1). When tumors reached the 
planned volume, they are irradiated with 2x5 Gy and then 
surgically removed at different time points after RT. 
Diffusion Weighted (DW) -MRI was performed every 2 days 
between RT and surgery. For each tumors we acquired 8 
slices of 1 mm thickness and 0.5 mm gap with an “in plane 
voxel resolution” of 0.5 mm. For DW-MRI, we performed 
FSEMS (Fast Spin Echo MultiSlice) sequences, with 9 different 
B-value (from 40 to 1000) and B0, in the 3 main directions. 
We also performed IVIM (IntraVoxel Incoherent Motion) 
analysis, in the aim to obtain information on intravascular 
diffusion, related to perfusion (F: perfusion factor) and 
subsequently tumor vessels perfusion.  
 
Results: With the MBA-MB 231 we observed a significant 
increase of F at day 6 after irradiation than a decrease and 
stabilization until surgery. No other modifications of the MRI 
signal, ADC, D or D* were observed. We observed similar 
results with 4T1 cells, F increased at day 3 than returned to 
initial signal (fig 1). The difference in the peak of F can be 
related to the difference in tumor growth between MBA-MB 
231 in four weeks and 4T1 in one week. 
 
 
Figure 1: Graphs representing F factor in tumor bearing mice 
before and after radiotherapy in MDA-MB 231(n=6) (Scid 
model) and in 4T1 (n=4) (BalbC model); (*=p<0, 05)  
 
Conclusion: For the first time, we demonstrate the 
feasibility of repetitive fMRI imaging in mice models after 
NeoRT. With these models, we show a significant difference 
between the pre-irradiated acquisition and day 6 or day 3 for 
perfusion F. This change occurs between the two previous 
time points of surgery demonstrating a difference in the 
metastatic spreading (1). These results are very promising for 
identifying noninvasive markers for guiding the best timing 
for surgery.  
Reference: (1) The timing of surgery after neoadjuvant 
radiotherapy influences tumor dissemination in a preclinical 
model Natacha Leroi et al. (2015) Oncotarget vol. 5 
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Purpose or Objective: To assess whether texture analysis of 
images obtained with Dual Energy CT (DECT) is related to 
KRAS and Ki-67 lung cancer biomarkers.  
 
Material and Methods: A retrospective review (May 2013 - 
January 2015) of 125 lung cancer patients with lung GSI 
(Gemstone Spectral Imaging) and perfusion CT imaging on a 
DECT was fulfilled. For 25 of them, the fraction of Ki-67 
positive-tumour cells was analysed and for 19 patients KRAS-
positive (mutation detected) or KRAS-negative (mutation not 
detected) character was evaluated (11 positive, 8 negative). 
DECT examination was performed on a Discovery CT 750 HD 
scanner (GE Healthcare, USA).  
For the perfusion exam, blood volume, blood flow and 
permeability-surface studies were analyzed. At GSI exam, 
images related to absorption in Hounsfield units (HU), iodine 
concentration and monochromatic virtual images 
reconstructed at 40, 60, 80, 100, 120 and 140 keV were 
assessed. Tumour fractal dimension was measured with the 
use of Mapfractalcount plug-in for ImageJ (National Institute 
of Health, USA) software.  
After extraction of DNA from paraffin embedded tissue using 
QIAamp DNA Investigator Kit (Qiagen), analysis of the KRAS 
gene exons 2 (codons 12/13) and 3 (codon 61) were 
performed in order to identify possible associated mutations 
with real-time PCR kit cOBAS® KRAS Mutation Test (Roche 
Diagnostics, SL).  
T-Student test or U Mann-Whitney test were used to compare 
differences between KRAS-positive from KRAS-negative 
cohorts. Pearson correlation coefficient was used to study 
linear relationship between fractal dimension and the 
fraction of Ki-67 positive-tumour cells.  
 
Results: Best result (p=0.02) for distinguishing KRAS-positive 
cohort was obtained for lesion fractal dimension at 140 keV 
virtual image. This parameter showed an AUC=0.80. It was 
predictive of KRAS-positive with 90.9% sensitivity and 75.0% 
specificity for a fractal dimension threshold of 2.352.  
There was a correlation of lesion fractal dimension in blood 
volume image and the fraction of Ki-67 positive-tumour cells 




Conclusion: Ki-67 positive-tumour cells and KRAS-positive 
biomarkers lead to tumour heterogeneity that modify 
radiographic image. Fractal dimension parameter quantifies 
such imaging heterogeneity and could allow to differentiate 
them.  
A higher fractal dimension (higher heterogeneity) of lesion at 
virtual monochromatic images is measured for KRAS-positive 
mutation, while a higher fraction of Ki-67 positive-tumour 
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